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Abstract
Hens have a tremendous capacity for producing polyclonal antibodies that can
subsequently be isolated in high concentrations from their eggs. An approach for
further maximizing their potential is to produce multiple antisera in the same
individual throughmultiplexed (multiple simultaneous) immunizations. An unknown
with this approach is how many immunogens a single bird is capable of mounting a
sizeable antigenic response toward. At what point does it become counter-productive
to add more immunogens to the same immunization regimen?
In the present study we were able to demonstrate that the competing effects of co-
administering multiple immunogens effectively limit the antibody specificities that can
be raised in a single individual to a fairly low number. Two potent model immunogens,
KLH and CRM197, were administered together with competing antigens in various
concentrations and complexities. With an upper limit of 1 mg protein material
recommended for chicken immunizations, we found that the maximum number of
immunogens that can be reliably used is most likely in the low double digits.
The limiting factor for a response to an immunogen could not be related to the
number of splenic plasma cells producing antibodies against it. When administer-
ing KLH alone, up to 70% of the IgY-producing splenic plasma cells were
occupied with producing anti-KLH antibodies; but when simultaneously being
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exposed to a plethora of other antigens, a response of a comparable magnitude
could be mounted with a splenic plasma cell involvement of less than 5%.
Two breeds of egg-layers were compared with respect to antibody production in an
initial experiment, but differences in antibody productivity were negligible.
Although our findings support the use of multiplexed immunizations in the hen, we
find that the number of immunogens cannot be stretched much higher than the
handful that has been used in mammalian models to date.
Keywords: Biotechnology, Immunology
1. Introduction
Polyclonal antibody production is a less sophisticated technology than is monoclonal
antibody production; yet, polyclonal antibodies make up a substantial share of the total
yearly sales in the antibody market. Polyclonals offer advantages in the production
stages: the antibodies can be produced simply, cheaply, and with a short turnover time
from purification of an immunogen to the isolation of an antiserum. Traditionally,
polyclonals are produced in mammalian species – rabbits being the most utilized
species – but a strong case has been made for using birds, specifically hens [1,2,3,4].
The principal advantage is that antibodies are deposited in the hens’ eggs through
maternal transfer [5,6]. The antibodies are then, with relative ease and a high degree of
purity, isolated from egg yolks [7,8]. The breeds used in modern egg-laying facilities
will lay an egg nearly every day [9] for a year from when the hen is 4–6 months old
[5,10], and healthy hens have been known to lay eggs well-past their tenth year [11].
With the egg yolk containing antibodies at concentrations similar to those in the hen’s
serum, a hen will in one month produce amounts of antibodies similar to those obtained
through blood samplings from a rabbit in an entire year [12,13].
Since the pioneering work of isolating chicken IgY (also sometimes referred to as
avian IgG) from eggs [14,15,16], a number of commercial companies have
established themselves on the polyclonal antibody market, offering chicken
antibodies for research and diagnostic use; however, their market share is limited.
A possible reason contributing to these companies’ lack of market penetration is their
inability to effectively utilize the capacity offered by the chicken in antibody
production. One approach for better utilizing this tremendous capacity is by
producing antiserum with multiple specificities in the same animal: Isolation and
purification methods for antibodies are easily scalable whereas housing and
husbandry of animals are not. By simultaneously producing multiple antisera in the
same animal, production costs and animal numbers can be reduced manifold [17,18].
Producing multivalent antiserum in an animal requires a solid understanding of
how the immune system responds to multiple simultaneous immunizations.
Immunizations with multiple immunogens (multiplexed immunizations) have been
used to great effect in mammalian species [18,19,20,21] – of particular note is the
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use of multiplexed immunizations in generating the Human Protein Atlas
[22,23,24] – and to a limited extent been explored in chickens [25,26,27]. Many
of the fundamental concepts are still poorly understood [28,29,30], however, and all
but unknown for birds. In the present study we set out to explore a fundamental
concept: to determine the number of antigens a single individual (bird) can respond to.
Working with a limited injection volume [2,31], it stands to reason that there must
be an upper limit to the number of immunogens that can be combined in one
immunization. In controlled immunizations more than ten immunogens have rarely
been used (e.g. [20]). But immunizations using whole, or fractionated, serum have
been long-used to generate antibodies against major serum proteins [32,33],
suggesting that the capacity for producing useful polyclonal serum is much higher.
Consequently we hypothesized that the hen’s immune system could be used to
generate polyclonal antiserum toward thousands of immunogens simultaneously.
Chickens lack lymph nodes and the Bursa of Fabricius – the organ responsible for
B-cell development in birds – involutes and appears to have little to no function in
adult birds [34]; consequently the spleen plays a central role in the mature hen’s
adaptive immune response [35]. If the capacity of the spleen to host plasma cells
for producing circulating antibodies is limited, and if a given number of plasma
cells is required for an adequate antigenic response, estimating the sizes of these
populations should offer a way of predictably estimating the maximum number of
antigens an individual can produce high-avidity antiserum against. To test our
hypothesis we designed experiments to identify the critical amount of a model
immunogen required to elicit a significant antigenic response, when administered
in the presence of a complex mixture of competing antigens. In addition, we set out
to quantify the number of splenic plasma cells associated with these responses.
Producing a matrix of competing antigens from commercially available purified
proteins would make for a prohibitively expensive study design given that we
expected to need thousands of unique species. Instead we opted for a reversed
design, starting with a natural source offering a complex composition of proteins,
and using chromatographic techniques to derive less complex matrices from this
source. In addition, we chose to investigate whether the antigenic response differed
greatly between two common breeds of laying hens.
2. Material and methods
2.1. Experiments
2.1.1. Experiment 1: comparing the antigenic response in two
chicken breeds
To determine whether there are large discrepancies between chicken breeds in
relation to antigenic response, we compared the response of two of the most
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common egg-laying breeds utilized at farms in Denmark: ISA Warren (n = 14) and
Lohmann LSL (n = 14). On day 0, when chickens were 21 weeks of age (4–6
weeks after any previous vaccinations), the hens were randomly allotted to receive
a subcutaneous immunization with KLH (Keyhole Limpet Hemocyanin) of up to
100 μg (Table 1). Blood samples were drawn immediately prior to booster
immunizations, which were given on days 14 and 28. A final blood sample was
drawn on day 33 before the experiment was terminated. Concentrations of IgY
antibodies against KLH (α-KLH IgY) and total circulating concentrations of IgY
were determined in the blood samples (EDTA plasma). When the experiment was
terminated, spleens were harvested from the Lohmann LSL hens receiving the
highest dose (to act as a reference in Experiment 3).
2.1.2. Experiment 2: titration of KLH and diphtheria toxin against
a mixture of competing antigens.
To determine the concentration at which an immunogen is able to elicit a
measurable antigenic response in the presence of a complex matrix of (competing)
proteins, Lohmann LSL hens (n = 50) were immunized with KLH, diphtheria toxin
and protein mixes of differing complexity (Table 2). The hens received their first
immunization (Day 0) at 14 weeks of age (12 weeks after any previous
vaccination) and were booster immunized on day 26. Blood samples (serum) were
drawn immediately prior to the boosting and on day 39. IgY and α-KLH IgY
concentrations were determined in the blood samples (serum).
2.1.3. Experiment 3: titration of competing antigens against a
constant dose of KLH
To determine the effect of a complex matrix of competing proteins on the antigenic
response toward a given immunogen, Lohmann LSL hens (n = 26) were
Table 1. Design for Experiment 1. Number of hens (n) immunized with a given
dose of KLH (in μg). The uneven subject distribution arose from a
miscommunication and practical constraints, but should have no effect on the
overall hypothesis tests.
KLH (μg) ISA Warren (n) Lohmann LSL (n)
0 2 2
0.030 – 2
0.16 3 2
0.80 2 2
2.4 2 –
4.0 2 2
12 2 2
100 1 2
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immunized with KLH and a protein mixture (Table 3). The hens received their first
immunization (Day 0) at 18 weeks of age (5 weeks after any previous vaccination).
Blood samples were drawn immediately prior to booster immunizations, which were
given on days 14 and 28. A final blood sample was drawn and spleens were harvested
on day 33. IgY/α-KLH IgY concentrations were determined in the blood samples
(EDTA plasma). Splenocytes were analyzed for cells producing IgY and α-KLH IgY.
2.2. Housing and husbandry
ISA Warren hens were purchased from Bangs Hønniker Aps (Hoejtoftegaard,
Denmark) and Lohmann LSL hens were purchased from Ova Production AB
Table 2. Design for Experiment 2. Number of hens (n) immunized with a given
dose of model immunogens (KLH and diphtheria toxin CRM197) and a mix of
competing proteins (numbered by increasing complexity from 1–3).
KLH (μg) CRM197 (μg) Mix 1 (μg) Mix 2 (μg) Mix 3 (μg) Lohmann LSL (n)
0 0 2
0.16 0.16 2
0.80 0.80 2
4.0 4.0 2
20 20 2
100 100 2
200 200 2
0 0 400 2
0.16 0.16 400 2
0.80 0.80 400 2
4.0 4.0 390 2
20 20 360 2
100 100 200 2
0 0 400 2
0.16 0.16 400 2
0.80 0.80 400 2
4.0 4.0 390 2
20 20 360 2
100 100 200 2
0 0 400 2
0.16 0.16 400 2
0.80 0.80 400 2
4.0 4.0 390 2
20 20 360 2
100 100 200 2
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(Vittinge, Sweden; Experiment 2) or Triova Aps (Herlufmagle, Denmark;
Experiment 3). Chickens involved in Experiments 1 and 3 were housed in groups
of up to 15 individuals (one rooster per cage). Pens, measuring 5.76 m2 (2.4 × 2.4
m, height 1.8 m), were lined with wood shavings and equipped with perches, nests
and a dust bath (sand and soil). Water and feed – a mixture of grains, corn and
pelleted diet (DLG a.m.b.a, Copenhagen, Denmark) – was supplied ad libitum and
food enrichment items (e.g. fruits, vegetables, seeds and mealworms) were
supplied daily. Room temperature was maintained at approximately 18 °C and
lights were controlled to give 14 hours of artificial daylight. Chickens involved in
Experiment 2 were housed in groups of 12–13 individuals (one rooster per cage).
Wire cages, measuring 2 m2 (2 × 1 m, height 0.55 m), were equipped with perches,
nests and a dust bath (finely crushed stone and wood shavings). Water and feed – a
mixture of grains, mussel shells and pelleted diet (AB Johan Hansson, Uppsala,
Sweden) – were supplied ad libitum. Room temperature was maintained at 18–22
°C and lights were controlled to give 15 hours of artificial daylight.
2.2.1. Procedures
For immunizations, the hens were restrained and a total of 400 μl of a 1:1 stable
immunogen/FIA (Freund’s incomplete adjuvant; Statens Serum Institut, Copenha-
gen, Denmark) emulsion was deposited subcutaneously in three injection sites on
the chest. Blood samples (approximately 2 ml) were drawn from the wing vein of
the hens into EDTA-treated vials (Experiments 1 and 3) or allowed to coagulate in
non-EDTA vials (Experiment 2). Blood samples were centrifuged at 5000 g for 10
Table 3. Design for Experiment 3. Number of hens (n) immunized with a given
dose of KLH and a mix of competing proteins (Mix 2 from Exp. 2).
KLH (μg) Mix (μg) Lohmann LSL (n)
0 0 2
0.16 0 2
0.16 25 2
0.16 50 2
0.16 100 2
0.16 200 2
0.16 400 2
0.80 0 2
0.80 25 2
0.80 50 2
0.80 100 2
0.80 200 2
0.80 400 2
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minutes and samples were decanted and stored at −20 °C until analysis. The hens
were euthanized by decapitation and spleens were dissected and immediately
placed into a cell culture medium.
2.2.2. Ethics statement
Experiments 1 and 3 were performed in AAALAC (Association for Assessment
and Accreditation of Laboratory Animal Care) International accredited facilities
under the supervision of a local ethics committee. All procedures were approved by
the Animal Experiments Inspectorate under the Danish Ministry of Food,
Agriculture and Fisheries (license number 2012-15-2934-00077). Experiment 2
was performed at Ova Production AB (Vittinge, Sweden) where all procedures
were approved by the regional Ethics Committee.
2.3. Antigens
Model immunogens, KLH (Sigma Aldrich, St. Louis MO, USA; cat. no. 70557)
and lyophilized diphtheria toxin variant CRM197 (Merck Millipore, Billerica MA,
USA; cat. no. 322327), were obtained from commercial vendors. Protein mixtures
of differing complexities, but comparable concentrations, were prepared by
isolating water soluble proteins from human placental tissue, chromatographical
fractionation, and pooling of select fractions.
2.3.1. Preparing a water-soluble protein starting material
Pooled and rinsed human placental tissue was processed into a course homogenate,
passed through a coarse sieve, and centrifuged to remove particulates (3 × 30
minutes at 20,000 g, 4 °C). The final supernatant was filtered, and stored at −20 °C
with 0.1 mM phenylmethylsulfonyl fluoride. The crude placental extract was then
processed to obtain a water-soluble protein fraction: The thawed material was
diluted 10-fold in a Tris buffer (20 mM Tris-HCl pH 7.4 with 150 mM NaCl),
ammonium sulphate was added (a saturated solution was added dropwise to obtain
a 50% solution) and the suspension was left to precipitate overnight at 4 °C. After
centrifugation (20,000 g, 30 minutes, 4 °C) the pellet was resuspended in Tris
buffer; insoluble proteins were separated by centrifugation and discarded.
2.3.2. Fractionation by size exclusion chromatography
The placental protein solution was fractionated batch-wise using size exclusion
chromatography on a HiLoad 26/60 Superdex200 pg column (GE Healthcare,
Chicago IL, USA) equilibrated in Tris buffer (cleaned between runs with 0.5 M
NaOH). Placental protein (100 mg, estimated by spectrophotometry at 280 nm, in 4
ml) was loaded, and 4 ml fractions were collected at flow rate 2.5 ml/min. Elution
profiles (recorded at 280 nm) were aligned and corresponding fractions were
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pooled across batches to form equal volume eluates. The pooled eluates were
concentrated using Amicon Ultra-15 centrifugal filters (Merck Millipore, Billerica
MA, USA) and combined to form three protein mixtures with comparable amounts
of total protein but differing levels of complexity.
2.3.3. SDS-PAGE
Pooled eluates and protein mixtures were separated and imaged by SDS-PAGE.
Samples were reduced in with 100 mM 1,4-Dithiothreitol in a loading buffer (10%
Glycerol, 50 mM Tris-HCl pH 6.8, 2% SDS, 0.01% Bromophenol blue), boiled for
2 minutes and loaded onto a freshly cast 11% polyacrylamide gel. Electrophoresis
was performed in a standard Tris-glycine buffer system at 70 V and 150 V to allow
migration of proteins through the stacking and separation gel, respectively. The
gels were stained with Coomassie Blue.
2.4. Enzyme-linked immunosorbent assays (ELISAs)
2.4.1. Sandwich ELISA for quantification of total IgY
Clear 96-well plates (Costar high binding; Corning Inc., Corning NY, USA)
were incubated (1 hour at 37 °C) with 100 μl/well 0.5 μg/ml goat anti-chicken
IgY (Southern Biotech, Birmingham AL, USA; cat. no. 6100-01). The plates
were washed in PBS (pH 7.4, 0.05% Tween 20), blocked (1 hour at 37 °C) with
200 μl/well PBS with 1% BSA and washed again. Chicken IgY standards
(Merck-Millipore; cat. no. AC146) and serum/plasma samples were diluted in
PBS (0.1% BSA) and analyzed in duplicate (100 μl/well, incubated 1 h at 37
°C). The plates were washed and 100 μl/well horseradish peroxidase (HRP)
conjugated rabbit anti-chicken IgY (Sigma Aldrich; cat. no. A9046), diluted
1:50,000 in PBS (0.1% BSA), was added. Following incubation (1 hour at 37
°C), the plates were washed before addition of 50 μl/well TMB (3,3′, 5,5′-
tetramethylbenzidine, Sigma Aldrich; cat. no. T0440). The plates were
developed for 30–40 minutes in the dark before the reaction was terminated
by adding 100 μl/well 1 M H2SO4 and absorbances were measured at 450 nm
(Multiskan EX; Thermo Fisher Scientific, Waltham MA, USA). The assay
showed excellent parallelism and an average spike recovery of 100% and 92%
for serum and plasma samples, respectively (spikes ranging from 0.3 to 1.6 ng/
ml; data available on request).
2.4.2. Indirect ELISA for quantification of antigen-specific titers
Clear 96-well plates were coated (1 hour at 37 °C or overnight at 4 °C) with 1 μg
KLH or 0.5 μg diphtheria toxin in 100 μl PBS. The plates were washed and
blocked and washed again. Serum and plasma samples were analyzed in duplicate.
An antigen-specific positive serum sample was serially diluted in PBS (0.1% BSA)
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to form a linear standard curve. Following incubation (1 hour, 37 °C) the plates
were washed and secondary antiserum (rabbit anti-chicken IgY:HRP, diluted
1:10,000 in PBS, 0.1% BSA) was added. Following incubation (1 hour at 37 °C)
the plates were washed and 50 μl/well TMB was added. After 10–15 minutes the
reaction was terminated by adding 100 μl/well 1 M H2SO4 and the absorbances
were measured at 450 nm.
2.5. Preparation of splenocytes
Dissected spleens were trimmed from fat and connective tissue and single cell
suspensions were prepared by forcing the passage of splenic tissue through a fine
metallic mesh back into fresh cell culture medium (RPMI 1640 with GlutaMAX;
Thermo Fisher Scientific) with 10% heat inactivated fetal bovine serum (Sigma
Aldrich), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma Aldrich). Cell
clusters were disrupted by pipetting and the neat suspension was transferred to new
tubes. The cells were washed by decanting the supernatant after centrifugation (10
minutes, 200 g), and subsequent resuspension in fresh medium. Splenocytes were
isolated from the cell suspension by density gradient centrifugation with
LymphoprepTM (Stemcell Technologies, Vancouver BC, Canada) according to
the manufacturer’s instructions. The isolated cells were washed again, counted in a
hemacytometer, and used for analysis immediately.
2.6. ELISPOT for splenic plasma cells
To quantitate antigen-specific splenic plasma cells an ELISPOT was utilized,
similar to what has been utilized in chickens in the past [36]. Mixed cellulose ester
membrane plates (MAHAS45010; Merck Millipore) were coated overnight at
room temperature with 1 μg goat anti-chicken IgY or 0.5 μg KLH in 100 μl PBS
pH 7.4. The plates were washed in PBS and 200 μl/well cell medium was added.
Following incubation for 2 hours, the plates were washed in PBS and splenocytes
(< 500,000 cells/well diluted in fresh cell medium) were added to the wells in
triplicate and plates were incubated for > 32 h in an incubator (40 °C and 5% CO2).
The plates were washed in PBS, 0.05% Tween 20 and incubated with 100 μl/well
rabbit anti-chicken IgY:HRP diluted 1:1000 in PBS (1% BSA) for 2 hours at 40 °C
and 5% CO2. The plates were washed in PBS, 0.05% Tween 20, and subsequently
PBS without Tween, before 100 μl/well 4-Chloro-1-Naphthol (Sigma Aldrich; cat.
no. C8302) was added. The plates were incubated for 45–60 minutes and the
reaction was stopped by thorough rinsing of the plates in Milli-Q water. Spots were
counted on the dried plates using an automated plate reader (CTL-ImmunoSpot S6;
CTL, Shaker Heights OH, USA). Numbers of plasma cells producing α-KLH IgY
was related to the total number of IgY-producing plasma cells in the same sample.
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2.7. Data treatment
The concentration of α-KLH IgY in samples was quantified in relation to an
aliquoted standard sample with a concentration defined as 1000 AU (arbitrary
units)/ml. To improve the ability to distinguish low levels of specific antibodies
from unspecific binding in the assay, samples were further normalized by
factoring in the sample total IgY concentration. To approximate a normal
distribution, data on circulating IgY concentrations and the normalized antigenic
responses were log-transformed prior to all analyses. A measurable antigenic
response was defined as a response exceeding the average of the pooled
negative controls (non-immunized hens) by two standard deviations. An
immunogen dose was considered eliciting a positive antigenic response only
when all the individuals receiving it produced a positive antigenic response.
Naïve serum samples were tested for initial differences using independent-
samples t-tests adjusted for unequal variances. Antigenic responses and total
circulating levels of IgY were tested separately. Inter-breed differences in
immune response were tested for using a repeated measures ANOVA design
with breed and immunogen dose (as a covariate) offered as predictors; degrees
of freedom were adjusted using Greenhouse-Geisser correction as error
covariances did not meet the requirement of sphericity. ANOVAs were also
used to test whether increasing complexity of the co-administered protein matrix
had a suppressive effect on the immune response toward the model
immunogens, by leaving out the individuals that received no competing protein
mix and offering group (the protein matrix used) and immunogen dose as
predictors. To allow for detection of small populations of α-KLH plasma cells
in the ELISPOT assay, wells were loaded with very high numbers of
splenocytes. This can potentially inflate the number of false positives. Thus,
to better establish a negative range when analyzing the data, the number of
α-KLH IgY producing splenocytes associated with detectable circulating levels
of α-KLH IgY was used. A positive response was defined as a number of
α-KLH IgY positive splenocytes exceeding the average of the negatives by two
standard deviations.
3. Results
3.1. Protein mixtures
The water-soluble placental proteins were separated using size exclusion
chromatography and a total of 13 fractions were pooled from nine batch-wise
fractionations: Fractions 1, 3, 5, 7, 9, 11, and a pool collecting all fractions from
13 and onward, were used to prepare Mix 1, 2, and 3 (Fig. 1). Mix 1 consisted of
a single fraction (7), Mix 2 consisted of three combined fractions (1, 7, and the
final fractions), and Mix 3 consisted of all the listed fractions.
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3.2. Experiment 1: comparing the antigenic response in two
chicken breeds
Both breeds of hen had a clear antigenic response toward immunizations with
KLH, with doses ≥ 0.8 μg KLH ensuring a measurable response – largely
comparable to the response against doses of 100 μg – in both breeds following
three successive immunizations (Fig. 2). Serum from naïve ISA Warren hens
(obtained on day 0, before immunizations) displayed higher levels of unspecific
binding than did serum from Lohmann LSL hens (T-test: t21 = −3.7, p < 0.001).
By contrast, the Lohmann LSL hens responded to the booster immunizations by
producing higher levels of circulating IgY (the effect of the interaction time ×
breed on total IgY concentrations: F1.7,38 = 21, p < 0.001). These differences in
dynamics of the antigenic response canceled out over time, however, with the
antigenic response toward KLH not differing significantly between the two breeds
(F1,22 = 0.001, p = 0.97).
3.3. Experiment 2: titration of KLH and diphtheria toxin against
a mixture of competing antigens.
Of the two simultaneously administered model immunogens KLH was the more
potent, eliciting a measurable antigenic response at doses ≥ 0.16 μg (as also found
[(Fig._1)TD$FIG]
Fig. 1. Composition and construction of protein mixes. Left: For an overview of the size-exclusion
chromatography, two UV (λ: 280 nm) absorption chromatograms (arbitrarily selected from 9 batch
runs) have been digitally traced from a paper source, been aligned, and the fractions used in
constructing the protein mixes have been defined. Top right: Reducing SDS-PAGE analysis of placental
protein fractions separated by size exclusion chromatography (15 μg loaded total protein per lane).
Molecular weight markers (numbers indicate size in kDa) have been included on both sides of the gel.
Bottom right: The three protein mixtures – post combination – analyzed by reducing SDS-PAGE (50 μg
total protein per lane).
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for Lohmann LSL in Exp. 1). By contrast, doses ≥ 0.8 μg had to be utilized to
ensure a response toward the diphtheria toxin. The antigenic response of both
model immunogens could be suppressed through the addition of protein mixtures
of differing complexity. The antigenic response could subsequently be rescued by
increasing the doses of the immunogens: KLH elicited a measurable response at
doses ≥ 4 μg whereas diphtheria toxin had to be supplied in doses ≥ 100 μg in
order for the antigenic response to reliably exceed background levels (Fig. 3). The
suppressive effect of the different matrices appeared to be independent of the
composition of the mixtures (Effect of mix on antigenic response at day 39: KLH,
F2,20 = 1.2, p = 0.31; CRM197, F2,19 = 3.1, p = 0.07) and relative abundance of
various placental proteins.
[(Fig._2)TD$FIG]
Fig. 2. Antigenic response toward KLH for ISA Warren and Lohmann LSL hens. Results are shown for
Day 14, after the primary immunization, and Day 33, after two booster immunizations (results for Day
28 are not shown). The two breeds did not appear to differ significantly in their antigenic response to the
immunogen (KLH); combining data from all birds, trends have been plotted (best-fit semi-log
interpolation lines with 95% CI, defined for responses exceeding the detection limit) outlining the dose-
response relationship. The (lower) detection limit for a positive response is indicated by the dashed line.
[(Fig._3)TD$FIG]
Fig. 3. Antigenic response toward KLH and diphtheria toxin (CRM197) on day 39. The immunogens
were provided either free of competing proteins (No mix) or in combination with proteins mixes of
increasing complexity (Mix 1–3, numbered in order of increasing complexity). An interfering effect can
be seen where co-immunizations with mixes reduce the antigenic response to the two model
immunogens. It is however not possible to discern a clear relationship in the extent of this interference
between the mixes of different complexity. The detection limits for a positive response are indicated by
the dashed lines.
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3.4. Experiment 3: titration of competing antigens against a
constant dose of KLH
Unlike our findings in the previous experiment, immunizations with 0.16 μg KLH
were insufficient to ensure a measurable antibody response in Lohmann LSL hens
(Fig. 4). Simultaneous immunization with 0.8 μg KLH and different amounts of
competing antigens resulted in a significant reduction of the KLH-specific
response which was fully suppressed in the presence of ≥200 μg placental protein
mixture.
Following three successive immunizations with 100 μg KLH, the population of
IgY-producing plasma cells specific for KLH constituted up to 70% of the total
number of IgY-producing plasma cells in the spleens of the immunized chickens.
Three successive immunizations with 0.8 μg KLH was capable of inducing an
antibody response equivalent in magnitude to 100 μg KLH. However, when
analyzing the number of α-KLH plasma cells in an ELISPOT, individuals with a
positive antigenic response toward 0.8 μg doses of KLH could not be distinguished
from individuals testing negative. This was also the case for α-KLH positive
individuals, who had received a competing protein matrix (Fig. 5).
4. Discussion
In trying to predict the number of simultaneous immunizations that can be used
successfully in a chicken model, we tried to characterize the mechanisms limiting
the number of simultaneous antigenic responses. We hypothesized that the number
of splenic plasma cells would be relatable to the antigenic response they were a
part of. The limited resources of the spleen coupled with a critical number of
plasma cells needed for a measurable immune response toward an immunogen
could then be used to estimate the number of antigens it could be administered in
the presence of. The fact that two antigenic responses of comparable magnitude
[(Fig._4)TD$FIG]
Fig. 4. Suppression of the antigenic response toward KLH (either 0.16 or 0.80 μg) by simultaneous
immunization with variable concentrations of a protein matrix (Mix 2 from Exp. 2). The detection limit
for a positive response is indicated by the dashed line.
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could be produced by wildly disparate numbers of plasma cells precluded this
approach however. Whereas it has previously been shown that plasma cell
populations and resulting circulating concentrations of IgG are not directly
correlated in humans [37,38], it was still quite surprising to find that the
concentration of circulating α-KLH IgY could in no way be predicted from the
splenic content of α-KLH IgY producing plasma cells. Circulating concentrations
of specific antibodies usable for polyclonal antibody production, could be
produced while recruiting 70% of the splenic plasma cells, but just as easily be
associated with less than 5%. This difference can possibly be explained as a greater
level of activation of the smaller population of plasma cells when the immune
system is under greater strain. But it is also possible that the magnitude of the
antigenic response is more directly related to populations of plasma cells
disseminated to other tissues – as has been demonstrated in some studies [39] –
such as bone marrow or mucosa-associated lymphoid tissue. Future studies into the
antigenic response toward immunizations in chickens would do well to focus not
only on the magnitude of the response, but also its localization.
For the present study, two potent model immunogens were used in order to avoid
non-responder individuals and to have a clear (“benchmark”) antigenic response
with which to work. This provides a “best case scenario” with respect to estimating
the capacity of a bird’s adaptive immune response: Lohmann LSL hens would, for
example, respond reliably to doses of KLH as low as 0.8 μg. When co-
administering the immunogens with a protein matrix, the response to low doses
could be suppressed. To rescue the response, the immunogen dose had to be
increased by more than an order of magnitude. We could not find a suppressing
effect of increasing the complexity of the matrix of competing proteins, but only
[(Fig._5)TD$FIG]
Fig. 5. Number of plasma cells producing antibodies toward KLH, as a percentage of the total
population of IgY-producing splenocytes, graphed as a function of the corresponding antigenic
response. Individuals immunized with 100 μg KLH, and no competing protein matrix, (No mix; from
Exp. 1) were included as a positive reference. The magnitude of a positive response to the
immunizations can in no way be predicted by the number of splenocytes participating in it, and in most
cases not even be discerned from a negative response. The detection limits for a positive response are
indicated by the dashed lines.
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from the absolute concentration of proteins. Whereas we cannot rule out our not
having reduced the complexity enough to see an effect – even the least complex
mix contained a high number of different proteins – it appears absolute
concentrations were more important for the suppressive effect.
It has been suggested that no more than 1 mg of protein material can, or for animal
welfare reasons should, be used in immunizing a hen [2,4]. With both KLH and
CRM197 producing high antigenic responses when administered in doses below 5
μg our initial hypothesis seemed to hold: pushing the limits slightly – using
multiple deposition sites to distribute a somewhat higher total volume – a single
individual could be immunized with thousands of immunogens at these doses. We
would be disappointed however: When co-administering the model immunogens
with a matrix of competing proteins we found that more than ten times higher
concentrations of both immunogens were needed to elicit a measurable antigenic
response. This greatly limits the number of proteins that can be used in a
multiplexed immunization. Although there will quite often be proteins/peptides
that the immune system will overlook, even a potent immunogen like CRM197 can
be completely overshadowed when co-administered with 400 μg of competing
proteins. With the tested model immunogens requiring doses of 4 μg (KLH) and
100 μg (CRM197) for a reliable response when multiplexed, the maximum number
of immunogens that can be provided at once shrinks significantly, suggesting a
number between 10 and 100. With the two proteins having proven to be extremely
immunogenic, it is likely that a true number of (less potent) immunogens that a hen
can elicit a usable − in the context of producing polyclonal antibodies – immune
response toward in a multiplexed immunization is barely in the double digits.
These findings agree well with a previous study in mice by De Masi and
collaborators who reported an average no-response rate of one-in-four when using
as few as ten immunogens [20].
Although we know that the immune system can produce immunoglobulins toward
scores of targets (whether defined as whole proteins or epitopes) at the same time,
only a few targets will give rise to immunoglobulin responses high enough for it to
make sense to isolate and purify them for analytical/diagnostic use. It is
furthermore hard to predict which epitopes will present the lucky few targets.
When utilizing multiplexed immunizations, increasing the number of immunogens
beyond a certain threshold is pointless. As the number of targets grows, so too does
the relative fraction of immunogens that do not elicit a usable immune response:
any gains that could be had from multiplexing the immunizations effectively being
negated by the increasing probability of the subjects not responding.
The suitability of two different chicken breeds for antibody production was also
analyzed in the present study. Here, we were able to find only limited differences
in the immune response between Lohmann LSL and ISA Warren. Similarly to a
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previous study [40], the differences we found were so slight that we could find no
reason to advocate one breed over the other for antibody production.
In conclusion, the present findings confirm that the hen’s immune system can be
directed to producing multiple antisera at the same time. For proteins such as KLH,
only minute concentrations need to be used to ensure circulating IgY
concentrations usable for isolating polyclonal serum when immunized alone.
When co-administered with other proteins, higher concentrations are needed to
ensure a predictable response. This greatly limits the number of immunogens that
can be multiplexed. At present we would recommend a cautious approach when
utilizing more than ten immunogens at once and we believe that more than a
hundred is a fruitless endeavor.
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